DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/cmgsl9/solid_tumors) has announced the addition of the "Asia Pacific Solid Tumors Market 2013-2019" report to their offering.
Asia-Pacific Solid Tumors Market to Reach $2.3 Billion by 2019
Asia Pacific Solid Tumors Market 2013-2019 provides in-depth analysis of four key therapeutic indications within the Asia-Pacific (APAC) solid tumors market - bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer - covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these four solid tumor types.
The value of the solid tumors market in the APAC region amounted to an estimated $1 billion in 2012 and is expected to register a modest Compound Annual Growth Rate (CAGR) of 12.3% to reach $2.3 billion in 2019. The key drivers for growth in this market include: new product approvals in ovarian, pancreatic and prostate cancers; expected launches from the promising ovarian and prostate cancer pipelines; and increased market penetration due to the anticipated implementation of social insurance in China. Conversely, the growth of the market in this region could face some restricting influences, including: the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; low access and penetration; and price erosion due to generic competition.
Key Topics Covered:
- Tables & Figures
- Solid Tumors Market in Asia Pacific to 2019 - Introduction
- Solid Tumors Market in Asia Pacific to 2019 - Therapeutic Landscape
- Solid Tumors Market in Asia Pacific to 2019 - Marketed Products
- Solid Tumors Market in Asia Pacific to 2019 - Pipeline Analysis
- Solid Tumors Market in Asia Pacific to 2019 - Market Forecast
- Solid Tumors Market in Asia Pacific to 2019 - Deals and Strategic Consolidations
- Solid Tumors Market in Asia Pacific to 2019 - Appendix
Products Featured
- Afinitor (everolimus)
- Avastin (bevacizumab)
- Carboplatin
- Cisplatin
- Doxorubicin
- Gemcitabine
- Jevtana (cabazitaxel)
- Paclitaxel
- Sutent (sunitinib)
- Tarceva (erlotinib)
- Taxotere (docetaxel)
- Zytiga (abiraterone acetate)
For more information visit http://www.researchandmarkets.com/research/cmgsl9/solid_tumors
